Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 309

1.

Prospective evaluation of qualitative and quantitative ¹⁸F-FDG PET-CT parameters for predicting survival in recurrent carcinoma of the cervix.

Maharjan S, Sharma P, Patel CD, Sharma DN, Dhull VS, Jain SK, Thulkar S, Malhotra A, Kumar R.

Nucl Med Commun. 2013 Aug;34(8):741-8. doi: 10.1097/MNM.0b013e3283622f0d.

PMID:
23676840
[PubMed - indexed for MEDLINE]
2.

Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38. doi: 10.1007/s00259-011-1934-6. Epub 2011 Sep 23.

PMID:
21946983
[PubMed - indexed for MEDLINE]
3.

Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography.

Yoo J, Choi JY, Moon SH, Bae DS, Park SB, Choe YS, Lee KH, Kim BT.

Int J Gynecol Cancer. 2012 Sep;22(7):1226-33. doi: 10.1097/IGC.0b013e318260a905.

PMID:
22810970
[PubMed - indexed for MEDLINE]
4.

Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.

Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19.

PMID:
22999369
[PubMed - indexed for MEDLINE]
5.

18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.

Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, Wong R, Fury M, Schöder H.

J Nucl Med. 2012 Oct;53(10):1506-13. doi: 10.2967/jnumed.111.101402. Epub 2012 Aug 14.

PMID:
22895812
[PubMed - indexed for MEDLINE]
Free Article
6.

The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration.

Burger IA, Vargas HA, Donati OF, Andikyan V, Sala E, Gonen M, Goldman DA, Chi DS, Schöder H, Hricak H.

Gynecol Oncol. 2013 Jun;129(3):586-92. doi: 10.1016/j.ygyno.2013.01.017. Epub 2013 Jan 29.

PMID:
23369941
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer.

Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM, Choi JY.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):50-8. doi: 10.1007/s00259-013-2530-8. Epub 2013 Aug 16.

PMID:
23948859
[PubMed - indexed for MEDLINE]
8.

Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.

Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT.

Ann Surg. 2013 Feb;257(2):364-70. doi: 10.1097/SLA.0b013e318262a6ec.

PMID:
22968069
[PubMed - indexed for MEDLINE]
9.

FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.

Chung HW, Lee KY, Kim HJ, Kim WS, So Y.

J Cancer Res Clin Oncol. 2014 Jan;140(1):89-98. doi: 10.1007/s00432-013-1545-7. Epub 2013 Nov 6.

PMID:
24194352
[PubMed - indexed for MEDLINE]
10.

Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.

Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, Lee JY, Lee KH, Kim BT.

Ann Surg Oncol. 2010 Jan;17(1):115-22. doi: 10.1245/s10434-009-0719-7. Epub 2009 Oct 14.

PMID:
19826877
[PubMed - indexed for MEDLINE]
11.

Prognostic value of pretreatment 18F-FDG PET/CT parameters including visual evaluation in patients with head and neck squamous cell carcinoma.

Koyasu S, Nakamoto Y, Kikuchi M, Suzuki K, Hayashida K, Itoh K, Togashi K.

AJR Am J Roentgenol. 2014 Apr;202(4):851-8. doi: 10.2214/AJR.13.11013.

PMID:
24660716
[PubMed - indexed for MEDLINE]
12.

Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.

Satoh Y, Onishi H, Nambu A, Araki T.

Radiology. 2014 Jan;270(1):275-81. doi: 10.1148/radiol.13130652. Epub 2013 Oct 28.

PMID:
24029640
[PubMed - indexed for MEDLINE]
13.

Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.

Vu CC, Matthews R, Kim B, Franceschi D, Bilfinger TV, Moore WH.

Nucl Med Commun. 2013 Oct;34(10):959-63. doi: 10.1097/MNM.0b013e32836491a9.

PMID:
23921784
[PubMed - indexed for MEDLINE]
14.

Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy.

Moon SH, Cho SH, Park LC, Ji JH, Sun JM, Ahn JS, Park K, Choi JY, Ahn MJ.

Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1005-13. doi: 10.1007/s00259-013-2400-4. Epub 2013 Apr 18.

PMID:
23595109
[PubMed - indexed for MEDLINE]
15.

Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma.

Choi ES, Ha SG, Kim HS, Ha JH, Paeng JC, Han I.

Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1836-42. doi: 10.1007/s00259-013-2511-y. Epub 2013 Jul 24.

PMID:
23880967
[PubMed - indexed for MEDLINE]
16.

Metabolic tumour volume and total lesion glycolysis, measured using preoperative 18F-FDG PET/CT, predict the recurrence of endometrial cancer.

Shim SH, Kim DY, Lee DY, Lee SW, Park JY, Lee JJ, Kim JH, Kim YM, Kim YT, Nam JH.

BJOG. 2014 Aug;121(9):1097-106; discussion 1106. doi: 10.1111/1471-0528.12543. Epub 2014 Jan 8.

PMID:
24397772
[PubMed - indexed for MEDLINE]
17.

Prognostic value of pretreatment 18F-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy.

Onal C, Reyhan M, Parlak C, Guler OC, Oymak E.

Int J Gynecol Cancer. 2013 Jul;23(6):1104-10. doi: 10.1097/IGC.0b013e3182989483.

PMID:
23792605
[PubMed - indexed for MEDLINE]
18.

18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.

Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, Lee J.

J Nucl Med. 2012 Sep;53(9):1337-44. doi: 10.2967/jnumed.111.098640. Epub 2012 Jun 29.

PMID:
22870824
[PubMed - indexed for MEDLINE]
Free Article
19.

Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer?

Akkas BE, Demirel BB, Dizman A, Vural GU.

Ann Nucl Med. 2013 Oct;27(8):756-63. doi: 10.1007/s12149-013-0745-1. Epub 2013 Jun 21.

PMID:
23793926
[PubMed - indexed for MEDLINE]
20.

Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.

Ryu IS, Kim JS, Roh JL, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY.

J Nucl Med. 2013 Jul;54(7):1032-8. doi: 10.2967/jnumed.112.116053. Epub 2013 May 13.

PMID:
23670902
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk